six The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV inside the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which include bosentan, sitaxentan and ambrisentan are oral therapies certified to be used in PAH. As no oral agent has shown superiority there continues to be discus